钆塞酸增强MRI衍生的功能性肝脏影像评分(FLIS)与脾直径预测晚期慢性肝病患者的结局
本研究纳入397例接受钆塞酸增强肝脏MRI的慢性肝病患者,计算基于肝胆期3项特征的FLIS并测量脾颅尾径(SCCD)。在代偿期晚期慢性肝病(cACLD)中,FLIS 0-3分和/或SCCD>13 cm者肝失代偿风险增高(aHR 3.07);在失代偿期(dACLD)中,FLIS 0-3分与ACLF风险独立相关(aHR 2.81);基于FLIS与SCCD的算法可独立预测无移植生存率。
要点
- cACLD患者中,FLIS 0-3分和/或SCCD>13 cm与肝失代偿风险增高独立相关(aHR 3.07)。
- dACLD患者中,FLIS 0-3分与ACLF风险增高独立相关(aHR 2.81)。
- 基于FLIS与SCCD的算法可对晚期慢性肝病的无移植生存概率进行分层(p<0.001)。
核心结论
- FLIS与SCCD是简单的影像学标志物,可为代偿期和失代偿期晚期慢性肝病的风险分层提供互补信息。
研究设计与样本
- 研究纳入397例接受钆塞酸增强肝脏MRI的慢性肝病患者,根据肝纤维化严重程度及肝失代偿存在/病史分为非ACLD、代偿期ACLD(cACLD)和失代偿期ACLD(dACLD)三组。
- FLIS通过汇总肝胆期3项特征(肝脏强化、胆道排泄、门静脉信号强度)的评分(0-2分)计算得出。
主要发现
- SCCD在观察者内和观察者间具有极好的一致性。
- 在cACLD患者中,SCCD是肝失代偿的独立危险因素(每cm;校正风险比[aHR] 1.13;95%CI 1.04-1.23;p=0.004)。
- cACLD患者中,FLIS 0-3分和/或SCCD>13 cm者肝失代偿风险增高(aHR 3.07;95%CI 1.43-6.59;p=0.004)。
- dACLD患者中,FLIS 0-3分与ACLF风险增高独立相关(aHR 2.81;95%CI 1.16-6.84;p=0.02),即使调整其他预后因素后仍显著。
- 基于FLIS和SCCD的算法可独立预测无移植生存率并对ACLD的无移植生存概率进行分层(p<0.001):FLIS 4-6分且SCCD≤13 cm者5年无移植生存率为84%,FLIS 4-6分且SCCD>13 cm者为70%,FLIS 0-3分者为24%。
关键数值与推荐
- cACLD患者中,FLIS 0-3分和/或SCCD>13 cm定义为肝失代偿风险增高组(aHR 3.07;95%CI 1.43-6.59;p=0.004)。
- dACLD患者中,FLIS 0-3分定义为ACLF风险增高组(aHR 2.81;95%CI 1.16-6.84;p=0.02)。
- 基于FLIS和SCCD的算法分层:FLIS 4-6分且SCCD≤13 cm者5年无移植生存率84%,FLIS 4-6分且SCCD>13 cm者70%,FLIS 0-3分者24%(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Functional liver imaging score (FLIS) - derived from gadoxetic acid-enhanced MRI - correlates with liver function and independently predicts liver-related mortality in patients with chronic liver disease (CLD), while splenic craniocaudal diameter (SCCD) is a marker of portal hypertension. The aim of this study was to investigate the accuracy of a combination of FLIS and SCCD for predicting hepatic decompensation, acute-on-chronic liver failure (ACLF), and mortality in patients with advanced CLD (ACLD). METHODS: We included 397 patients with CLD who underwent gadoxetic acid-enhanced liver MRI. The FLIS was calculated by summing the points (0-2) of 3 hepatobiliary-phase features: hepatic enhancement, biliary excretion, and portal vein signal intensity. Patients were stratified into 3 groups according to liver fibrosis severity and presence/history of hepatic decompensation: non-ACLD, compensated ACLD (cACLD), and decompensated ACLD (dACLD). RESULTS: SCCD showed excellent intra- and inter-reader agreement. Importantly, SCCD was an independent risk factor for hepatic decompensation in patients with cACLD (per cm; adjusted hazard ratio [aHR] 1.13; 95% CI 1.04-1.23; p = 0.004). Patients with cACLD and a FLIS of 0-3 points and/or a SCCD of >13 cm were at increased risk of hepatic decompensation (aHR 3.07; 95% CI 1.43-6.59; p = 0.004). In patients with dACLD, a FLIS of 0-3 was independently associated with an increased risk of ACLF (aHR 2.81; 95% CI 1.16-6.84; p = 0.02), even after adjusting for other prognostic factors. Finally, a FLIS and SCCD-based algorithm was independently predictive of transplant-free mortality and stratified the probability of transplant-free survival (TFS) in ACLD (p <0.001): FLIS 4-6 and SCCD ≤13 cm (5-year TFS of 84%) vs. FLIS 4-6 and SCCD >13 cm (5-year TFS of 70%) vs. FLIS 0-3 (5-year TFS of 24%). CONCLUSION: The FLIS and SCCD are simple imaging markers that provide complementary information for risk stratification in patients with compensated and decompensated ACLD. LAY SUMMARY: Magnetic resonance imaging (MRI) can be used to assess the state of the liver. Previously the functional liver imaging score, which is based on MRI criteria, was developed as a measure of liver function and to predict the risk of liver-related complications or death. By combining this score with a measurement of spleen diameter, also using MRI, we generated an algorithm that could predict the risk of adverse liver-related outcomes in patients with advanced chronic liver disease.
引用
- Bastati N, Beer L, Ba-Ssalamah A, et al. Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD. J Hepatol. 2022. PMID: 35525337. doi:10.1016/j.jhep.2022.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。